Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases

Abstract

Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

1 . A pharmaceutical composition for the treatment and prevention of a disease syndrome, comprising:
 (a) a therapeutically effective amount of a compound represented by Formula I:   
       
         
           
           
               
               
           
         
         wherein 
         R 1  and R 2  are each independently hydrogen, halogen, alkoxy, hydroxy or lower alkyl having 1 to 6 carbon atoms; 
         R 3 , R 4 , R 5 , R 6 , R 7  and R 8  are each independently hydrogen, hydroxy, C 1 -C 20  alkyl, alkene or alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, or two substituents of R 3  to R 8  may be taken together to form a cyclic structure; and 
         n is 0 or 1, with proviso that when n is 0, carbon atoms adjacent to n form a cyclic structure via a direct bond; or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and 
         (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof. 
       
     
     
         2 . The composition according to  claim 1 , wherein the compound of Formula I is selected from compounds of Formulae II and III: 
       
         
           
           
               
               
           
         
         wherein, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7  and R 8  are as defined in Formula I. 
       
     
     
         3 . The composition according to  claim 1 , wherein each R 1  and R 2  is hydrogen. 
     
     
         4 . The composition according to  claim 2 , wherein the compound of Formula II is a compound of Formula IIa wherein R 1 , R 2  and R 4  are independently hydrogen, or a compound of Formula IIb wherein R 1 , R 2  and R 6  are independently hydrogen: 
       
         
           
           
               
               
           
         
       
     
     
         5 . The composition according to  claim 2 , wherein the compound of Formula III is a compound of Formula IIIa wherein R 1 , R 2 , R 5 , R 6 , R 7  and R 8  are independently hydrogen: 
       
         
           
           
               
               
           
         
       
     
     
         6 . The composition according to  claim 1 , wherein the disease syndrome includes obesity, diabetes, a metabolic syndrome, a degenerative disease and a mitochondrial dysfunction-related disease. 
     
     
         7 . The composition according to  claim 6 , wherein the metabolic syndrome is obesity, an obesity complication, a liver disease, arteriosclerosis, cerebral apoplexy, myocardial infarction, a cardiovascular disease, an ischemic disease, diabetes, a diabetes-related complication or an inflammatory disease. 
     
     
         8 . The composition according to  claim 7 , wherein the diabetes-related complication is hyperlipidemia, hypertension, retinopathy or renal failure. 
     
     
         9 . A use of a compound of Formula I according to  claim 1  in the preparation of a drug for the treatment or prevention of a disease syndrome.